Abstract:Xin Yao, 1 Qingyu Wang, 1 Changge Han, 1 Jiaojiao Nie, 1 Yaotian Chang, 1 Lipeng Xu, 1 Bingya Wu, 1 Jingtian Yan, 1 Zhiyuan Chen, 1 Wei Kong, 1, 2 Yuhua Shi, 1 Yaming Shan 1, 2 1 National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, 130012, People's Republic of China; 2 Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, Jilin, 130012, People's Republic of China Correspondence: Yaming Shan, School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun, Jilin, 130012, People's Republic of China, Tel +86 133 2446 4361, Email Introduction: Broadly neutralizing antibodies (bNAbs) have the ability to neutralize a considerable breadth of genetically diverse human immunodeficiency virus (HIV) strains. Passive immunization can potentially provide protection against HIV infection in animal models. However, the direct antibody infusion effect is limited due to the short half-life and deficient immunogenicity of the antibody. As an alternative strategy, we propose the use of nano viral vectors, specifically the adeno-associated virus (AAV), to continuously and systematically produce bNAbs against HIV. Methods: Plasmids expressing bNAbs PG9, PG16, 10E8, and NIH45-46 antibodies were constructed, targeting three different epitopes of HIV. Additionally, the bNAbs gene mediated by rAAV8 was administered to generate long-term expression with a single injection. We established both single and combined immunization groups. The neutralizing activity of antibodies expressed in mice sera was subsequently evaluated. Results: The expression of bNAbs in BALB/c mice can last for > 24 weeks after a single intramuscular injection of rAAV8. Further studies show that neutralization of the HIV pseudovirus by sera from co-immunized mice with rAAV8 expressing 10E8 and PG16 was enhanced compared with mice immunized with 10E8 or PG16 alone. Conclusion: The prolonged expression of neutralizing antibodies can be maintained over long periods in BALB/c mice. This combined immunization is a promising candidate strategy for HIV treatment. Graphical Keywords: AAV delivery, HIV therapy, passive immunotherapy, combined immunotherapy Graphical The envelope glycoprotein (Env) of the human immunodeficiency virus (HIV) is the only virus-encoded protein present on the virion surface. The precursor of HIV Env is gp160, which is cleaved by furin into a heterodimer consisting of surface glycoprotein gp120 and transmembrane glycoprotein gp41. 1 Functional Env manifests as a trimer of gp120-gp41 heterodimers on the surface of infectious virions. 2 gp120 binds to cellular proteins CD4 and CCR5/CXCR4, whereas gp41 mediates the fusion between the virus and the host cell membrane. 3 Broadly neutralizing antibodies (bNAbs) are capable of recognizing a myriad of HIV-1 strains, including those less susceptible to surface alterations, and effectively decrease HIV-1 levels in the human body by inhibiting their replication. 4 These antibodies play a crucial role in preventing the virus from invading target cells, finalizing intracellular assembly, and releasing new viral particles. Furthermore, they increase viral clearance via phagocytosis 5 and eradicate infected cells through an FcγR-dependent mechanism. 6 Neutralizing antibodies also inhibit HIV-1 cell-to-cell spread. 7 The analysis of these antibodies revealed four major vulnerable sites of the Env virus, namely, the CD4 binding site (CD4bs), 8 gp120 interface trimerization glycan-dependent epitopes on variable loop 1 and variable loop 2 (V1/V2) on body apex 9 or variable loop 3 (V3), 10 and the membrane proximal outer region (MPER) of gp41. 11 Long-term treatment of HIV-1 infection necessitates repetitive injections due to the antibodies' short half-life within the body. 12 Adeno-associated virus (AAV) vectors exhibit potential as gene vectors for treating HIV-1 infection owing to their desirable gene delivery properties, nonpathogenic nature, and lack of immunotoxicity. 13,14 Moreover, utilizing the self-complementary double-stranded DNA form of the vector genome facilitates faster expression dynamics. 15 AAV vectors can be further optimized by engineering and fine-tuning viral capsids to enhance their transmission properties. 16 To date, at least 18 preclinical and clinical rAAV studies have been conducted related to HIV-1 res -Abstract Truncated-

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

HIV-1 Gp41-Targeting Fusion Inhibitory Peptides Enhance the Gp120-Targeting Protein-Mediated Inactivation of HIV-1 Virions

A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent Hiv-1 Inhibitors Based on Single Human Cd4 and Antibody Domains

A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins <subtitle>Combination of SAMT10 and SFT against HIV-1</subtitle>

A Bivalent Recombinant Protein Inactivates Hiv-1 by Targeting the Gp41 Prehairpin Fusion Intermediate Induced by Cd4 D1d2 Domains

Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface.

Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells

Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1

Molecular Insights into the Inhibition of HIV-1 Infection Using a CD4 Domain-1-specific Monoclonal Antibody

HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells

Combined Nano-Vector Mediated-Transfer to Suppress HIV-1 Infection with Targeted Antibodies in-vitro

An Amphipathic Peptide Targeting the Gp41 Cytoplasmic Tail Kills HIV-1 Virions and Infected Cells

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies

Glycosylphosphatidylinositol- Anchored Anti-Hiv Scfv Efficiently Protects Cd4 T Cells from Hiv-1 Infection and Deletion in Hu-Pbl Mice